CD8A and neoplasm: In a study of ovarian cancer, the addition of DKK1 inhibitor DKN-01 or anti-PD-1 therapy did not enhance the antitumor effect of PORCN inhibitor CGX-1321, although the use of CGX-1321 monotherapy significantly reduced tumor burden and increased CD8+ T-cell levels [213].